ofloxacin has been researched along with grepafloxacin in 52 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 23 (44.23) | 18.2507 |
2000's | 25 (48.08) | 29.6817 |
2010's | 4 (7.69) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sasabe, H; Sugiyama, Y; Tsuji, A | 1 |
Nezu, JI; Ohashi, R; Oku, A; Sai, Y; Shimane, M; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
Keserü, GM | 1 |
Nagashima, R; Nishikawa, T; Tobita, M | 1 |
Jia, L; Sun, H | 1 |
Larruskain, J; Montes, M; Orden, B; Perez-Trallero, E; Tamayo, E | 1 |
Sen, S; Sinha, N | 1 |
Imai, YN; Oiki, S; Ryu, S | 1 |
Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
Mitsuhashi, S; Wakebe, H | 1 |
Sanders, CC; Thomson, KS | 1 |
Bale, MJ; Erwin, ME; Jones, RN | 1 |
Hammerschlag, MR; Montalban, G; Roblin, PM | 1 |
Cartwright, FD; Kenny, GE | 1 |
Neumann, T; Patton, M; Reichart, C; Zenilman, JM | 1 |
Hecht, DW; Wexler, HM | 1 |
Goldstein, EJ | 1 |
Barry, AL; Fuchs, PC | 1 |
Barry, AL; Brown, SD; Fuchs, PC | 1 |
Goldsmith, CE; Moore, JE; Murphy, PG | 1 |
Dencer, C; Felmingham, D; Ridgway, GL; Robbins, MJ; Salman, H | 1 |
Deschilder, I; Liekens, K; Lontie, M | 1 |
Hashimoto, Y; Inui, K; Ito, T; Matsuo, Y; Yano, I | 1 |
Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
North, DS | 1 |
Hashimoto, Y; Inui, K; Ito, T; Masuda, S; Yano, I | 1 |
Bébéar, C; Bébéar, CM; Leblanc, F; Renaudin, H; Schaeverbeke, T | 1 |
Hashimoto, K; Minami, T; Owen, K; Takizawa, T; Yamashita, S | 1 |
Fourche, J; Leblanc, F; Maugein, J; Pellegrin, JL; Vacher, S | 1 |
Hooper, DC | 2 |
Amsterdam, D; Hardy, D; Mandell, LA; Rotstein, C | 1 |
Bjarnason, J; Blondeau, JM; Laskowski, R; Stewart, C | 1 |
Hashimoto, Y; Inui, K; Ito, T; Yano, I | 1 |
Hashimoto, Y; Inui, KI; Yamaguchi, H; Yano, I | 1 |
Doern, GV; Ernst, EJ; Klepser, ME; Petzold, CR; Rhomberg, P | 1 |
Johnson, AP; Livermore, DM; Warner, M | 1 |
Asherov, J; Dan, M; Poch, F | 1 |
Adachi, F; Hirota, M; Kamikawa, K; Kanegasaki, S; Nakata, K; Totsu, T; Watanabe, J | 1 |
Ball, P | 1 |
Inui, K; Saito, H; Yamaguchi, H; Yano, I | 3 |
Evans, ME | 1 |
Fujimoto, K; Hirota, M; Kaneki, T; Koizumi, T; Kubo, K; Ogasawara, H; Yamamoto, H; Yamazaki, Y | 1 |
Baumann-Wilschke, I; Rücker, M; Shakibaei, M; Stahlmann, R | 1 |
Fujimura, A; Hakamata, Y; Hirota, M; Hishikawa, S; Kobayashi, E; Miyamoto, G; Mizuta, K | 1 |
Bermejo, MV; Cantón, E; Orero, A; Pemán, J; Velert, MM | 1 |
Dalhoff, A; Shalit, I | 1 |
Di Bonaventura, G; Picciani, C; Piccolomini, R; Spedicato, I | 1 |
Asari, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Osaka, Y; Yasuda, S | 1 |
6 review(s) available for ofloxacin and grepafloxacin
Article | Year |
---|---|
Quinolone antibiotics.
Topics: | 2019 |
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Safety; Syndrome | 1996 |
New fluoroquinolone antibiotics.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Piperazines; Respiratory Tract Infections | 1999 |
New uses for new and old quinolones and the challenge of resistance.
Topics: Anti-Infective Agents; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Respiratory Tract Infections; Sensitivity and Specificity; Sexually Transmitted Diseases; Urinary Tract Infections | 2000 |
The fluoroquinolones after ciprofloxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Naphthyridines; Ofloxacin; Piperazines; Respiratory Tract Infections; Sexually Transmitted Diseases, Bacterial; Skin Diseases, Bacterial; Urinary Tract Infections | 2000 |
Immunomodulatory effects of quinolones.
Topics: Adjuvants, Immunologic; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clinical Trials as Topic; Cytokines; Fluoroquinolones; Humans; Immune System; Models, Animal; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2003 |
1 trial(s) available for ofloxacin and grepafloxacin
Article | Year |
---|---|
Crossover assessment of serum bactericidal activity of grepafloxacin, ofloxacin and clarithromycin against respiratory pathogens after oral administration to healthy volunteers.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Blood Bactericidal Activity; Clarithromycin; Cross-Over Studies; Female; Fluoroquinolones; Haemophilus influenzae; Humans; In Vitro Techniques; Klebsiella pneumoniae; Male; Moraxella catarrhalis; Ofloxacin; Penicillin Resistance; Piperazines; Respiratory Tract Infections; Streptococcus pneumoniae | 2001 |
45 other study(ies) available for ofloxacin and grepafloxacin
Article | Year |
---|---|
Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
Topics: Animals; Anti-Infective Agents; Bile; Biological Transport, Active; Fluoroquinolones; Glucuronates; Glutathione; Hyperbilirubinemia; Male; Piperazines; Quinolones; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley | 1998 |
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
Topics: Biological Transport, Active; Carnitine; Carrier Proteins; Cations; Cells, Cultured; Dose-Response Relationship, Drug; Embryo, Mammalian; Humans; Hydrogen-Ion Concentration; Kidney; Membrane Proteins; Organic Cation Transport Proteins; Sodium; Solute Carrier Family 22 Member 5; Stereoisomerism | 1999 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
Topics: Adult; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Mutation; Prospective Studies; Spain; Streptococcal Infections; Streptococcus pyogenes | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship | 2013 |
Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerases, Type II; Fluoroquinolones; Gram-Positive Bacteria; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Piperazines; Quinolones; Staphylococcus aureus | 1992 |
Dissociated resistance among fluoroquinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Mutation; Ofloxacin; Piperazines; Quinolones | 1994 |
Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control S
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ceftizoxime; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quality Control; Quinolones; Reference Values; Spiro Compounds; Thienamycins | 1994 |
In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Chlamydophila pneumoniae; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones | 1994 |
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
Topics: Anti-Infective Agents; Fluoroquinolones; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma pneumoniae; Ofloxacin; Piperazines; Quinolones; Ureaplasma urealyticum | 1993 |
Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Ofloxacin; Penicillin Resistance; Piperazines; Quinolones; Tetracycline Resistance | 1993 |
In vitro susceptibility of anaerobes to quinolones in the United States.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Culture Media; Drug Resistance, Microbial; Evaluation Studies as Topic; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Quinolones; United States | 1996 |
Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Ciprofloxacin; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Mutation; Ofloxacin; Piperazines; Quinolones | 1997 |
Is Escherichia coli ATCC 25922 useful for monitoring broth microdilution tests of fluoroquinolones?
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Reproducibility of Results | 1997 |
Pneumococcal resistance in the UK.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Chloramphenicol; Ciprofloxacin; Drug Resistance, Multiple; Fluoroquinolones; Humans; Macrolides; Microbial Sensitivity Tests; Northern Ireland; Ofloxacin; Oxacillin; Penicillin Resistance; Penicillins; Piperazines; Pneumococcal Infections; Quinolones; Retrospective Studies; Streptococcus pneumoniae; Tetracycline | 1997 |
The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chlamydia; Clarithromycin; Dose-Response Relationship, Drug; Doxycycline; Fluoroquinolones; Gram-Negative Bacteria; Legionella; Mycoplasma; Ofloxacin; Piperazines; Quinolones; Ureaplasma urealyticum | 1997 |
In vitro activity of newer quinolones on Streptococcus pneumoniae isolated from outpatients.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Cefuroxime; Cephalosporins; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Humans; Naphthyridines; Ofloxacin; Outpatients; Penicillin G; Penicillins; Piperazines; Pneumococcal Infections; Quinolones; Roxithromycin; Streptococcus pneumoniae | 1998 |
Transport of quinolone antibacterial drugs in a kidney epithelial cell line, LLC-PK1.
Topics: 4-Chloromercuribenzenesulfonate; Animals; Anti-Infective Agents; Cyclosporine; Epithelial Cells; Fluoroquinolones; Hydrogen-Ion Concentration; Kidney; Levofloxacin; LLC-PK1 Cells; Ofloxacin; Piperazines; Quinolones; Swine | 1998 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
Common questions about the newer fluoroquinolone antibiotics.
Topics: Anti-Infective Agents; Drug Interactions; Fluoroquinolones; Humans; Naphthyridines; Ofloxacin; Patient Selection; Piperazines; United States; United States Food and Drug Administration | 1999 |
Distribution characteristics of levofloxacin and grepafloxacin in rat kidney.
Topics: Animals; Anti-Infective Agents; Carbon Radioisotopes; Cimetidine; Dose-Response Relationship, Drug; Fluoroquinolones; In Vitro Techniques; Kidney Cortex; Kinetics; Levofloxacin; Male; Ofloxacin; p-Aminohippuric Acid; Piperazines; Rats; Rats, Wistar; Tetraethylammonium; Tissue Distribution | 1999 |
In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas.
Topics: Anti-Infective Agents; Ciprofloxacin; Doxycycline; Erythromycin; Fluoroquinolones; Microbial Sensitivity Tests; Mycoplasma; Ofloxacin; Piperazines; Ureaplasma urealyticum | 1999 |
The comparative arthropathy of fluoroquinolones in dogs.
Topics: Animals; Anti-Infective Agents; Body Weight; Ciprofloxacin; Dogs; Eating; Fluoroquinolones; Joint Diseases; Male; Ofloxacin; Piperazines; Synovial Fluid | 1999 |
Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Macrophages; Microbial Sensitivity Tests; Monocytes; Mycobacterium; Mycobacterium avium Complex; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Piperazines; Tuberculosis | 1999 |
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Transepithelial transport of levofloxacin in the isolated perfused rat kidney.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Biological Transport; Carbon Radioisotopes; Cimetidine; Coloring Agents; Enzyme Inhibitors; Epithelial Cells; Evans Blue; Fluoroquinolones; In Vitro Techniques; Inulin; Kidney; Levofloxacin; Male; Ofloxacin; p-Aminohippuric Acid; Perfusion; Piperazines; Rats; Rats, Wistar; Tetraethylammonium; Urine | 2000 |
Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
Topics: Anti-Infective Agents; Biological Transport; Caco-2 Cells; Cyclosporine; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Intestinal Mucosa; Levofloxacin; Metabolic Clearance Rate; Ofloxacin; Piperazines | 2000 |
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae; Time Factors | 2001 |
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae | 2001 |
Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages.
Topics: Anti-Infective Agents; Antitubercular Agents; Biological Transport; Cells, Cultured; Culture Media; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium; Ofloxacin; Piperazines | 2001 |
Safety of the new fluoroquinolones compared with ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines | 2000 |
Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2.
Topics: Adenosine Triphosphate; Anti-Infective Agents; Biological Transport; Caco-2 Cells; Carbon Radioisotopes; Chlorides; Cyclosporine; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Intestinal Mucosa; Levofloxacin; Ofloxacin; Piperazines | 2001 |
Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Streptococcus pneumoniae | 2001 |
Lung tissue distribution after intravenous administration of grepafloxacin: comparative study with levofloxacin.
Topics: Animals; Anti-Infective Agents; Epithelium; Fluoroquinolones; Infusions, Intravenous; Levofloxacin; Lung; Lymph; Molecular Structure; Ofloxacin; Piperazines; Pulmonary Circulation; Sheep; Time Factors | 2002 |
Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
Topics: Animals; Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Biological Availability; Cyclosporine; Enzyme Inhibitors; Fluoroquinolones; Genes, MDR; Intestinal Mucosa; Kidney; Levofloxacin; Liver; Male; Mice; Mice, Knockout; Ofloxacin; Piperazines; Rats; Tissue Distribution | 2002 |
Ultrastructural characterization of murine limb buds after in vitro exposure to grepafloxacin and other fluoroquinolones.
Topics: Abnormalities, Drug-Induced; Animals; Anti-Infective Agents; Calcium; Dose-Response Relationship, Drug; Embryo, Mammalian; Female; Fluoroquinolones; In Vitro Techniques; Levofloxacin; Limb Buds; Magnesium; Male; Mice; Mice, Inbred Strains; Ofloxacin; Piperazines; Pregnancy; Quinolones | 2002 |
Fluoroquinolone concentrations in plasma, urine, and bile after oral administration in rats with renal failure: useful technique for long-term bile collection.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Bile; Blood Urea Nitrogen; Fluoroquinolones; Levofloxacin; Male; Ofloxacin; Osmolar Concentration; Piperazines; Rats; Rats, Wistar; Reference Values; Renal Insufficiency; Specimen Handling | 2001 |
[Influence of ion pump-inhibiting drugs on the accumulation of ofloxacin and grepafloxacin in human polymorphonuclear leukocytes].
Topics: Anti-Infective Agents; Calcium Channel Blockers; Digoxin; Enzyme Inhibitors; Fluoroquinolones; Humans; Ion Pumps; Neutrophils; Ofloxacin; Omeprazole; Piperazines; Verapamil | 2002 |
Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.
Topics: Acute Kidney Injury; Animals; Anti-Infective Agents; Antineoplastic Agents; Bile Ducts; Biological Availability; Blotting, Western; Caco-2 Cells; Ciprofloxacin; Cisplatin; Duodenum; Fluoroquinolones; Humans; Injections, Intravenous; Levofloxacin; Male; Ofloxacin; Piperazines; Rats; Rats, Wistar; Time Factors | 2004 |
E-test method for detecting antibiotic synergy against Pseudomonas aeruginosa from neutropenic patients: a cost-effective approach.
Topics: Anemia; Anti-Bacterial Agents; Cefotaxime; Ceftriaxone; Cost-Benefit Analysis; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Hematologic Neoplasms; Humans; Levofloxacin; Microbial Sensitivity Tests; Neutropenia; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections | 2004 |
The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo.
Topics: Biological Transport; Carnitine; Cell Line, Tumor; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Ofloxacin; Organic Cation Transport Proteins; Piperazines; Placenta; Sodium; Solute Carrier Family 22 Member 5 | 2008 |